A retrospective observational study assessing use of PD-1 and PD-L1 inhibitors after first-line therapy in esophageal cancer patients in the US
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 09 Nov 2021 New trial record